Dr. Honghong Zhu | Colorectal Cancer | Best Researcher Award

Dr. Honghong Zhu | Colorectal Cancer | Best Researcher Award

Zhejiang Chinese Medical University | China

Author Profile

Scopus

Biography of Hong-Hong Zhu, MD, MSc, PhD – Professor of Extraordinary Ability 🎓🌍

🎯 Current Role: Leader in Medical Research

Dr. Hong-Hong Zhu is the Head of the Center for Medical Research at Zhejiang Chinese Medical University Affiliated Four-Province-Bordering Hospital of Traditional Chinese Medicine (Quzhou Hospital of TCM). Her leadership in medical research spans over three decades.

📜 Educational Background

  • Ph.D. in Epidemiology from Johns Hopkins University (JHU) Bloomberg School of Public Health (2007)
  • Postdoctoral Training at the U.S. National Institutes of Health (NIH)
  • MD & Master’s Degree in Medicine from Zhejiang University
  • M.Sc. from Clemson University

💡 Key Contributions: Breast Cancer Etiology Pioneer

Dr. Zhu was the first to propose the Synergistic Interaction Theory for breast cancer, linking environmental carcinogens and exogenous hormone use. Her work has significantly advanced the understanding of cancer causes.

🔬 Innovator in Colorectal Cancer Prevention

With 32 years of research in colorectal cancer prevention, Dr. Zhu and her team developed cost-effective screening methods that have saved millions of lives worldwide.

🏆 Academic Achievements and Awards

  • 135 Publications in esteemed journals
  • 35 Awards, including:
    • Best Poster Award (NIH) for breast cancer research (2006)
    • Delta Omega Honor from the U.S. National Public Health Honor Society (2007)
    • Second Place in Scientific Competition in Epidemiology and Public Health (2007)
    • Professor of Extraordinary Ability (2015)
    • Sigma Xi Scientific Research Honor (2024)

📚 Editor and Peer Reviewer

  • Editor-in-Chief of the Journal of GHR (since 2015)
  • Peer Reviewer for academic journals for over 20 years
  • Grant Reviewer for the U.S. Department of Health and Human Services (12 years)

Dr. Hong-Hong Zhu’s contributions to medical research have made her a global figure in epidemiology and cancer prevention.

🔍 Conclusion

With over three decades of research in epidemiology and disease prevention, Dr. Hong-Hong Zhu has made groundbreaking contributions in breast and colorectal cancer research. Her innovative approaches to cancer screening and prevention have been life-saving on a global scale. She remains a recognized leader in public health, continuing to inspire through her research, publications, and numerous honors. 🌟

 

📊🔬NOTABLE PUBLICATION:

 

  • Combining FITs and HRFQ with colonoscopy improve the cost-effectiveness of a 9-year mass colorectal cancer screening program
    Authors: Cai, S.-R., Huang, Y.-Q., Li, Q.-R., Yang, J.-H., Zheng, S.
    Journal: ESMO Open
    Year: 2024

 

  • Sex difference in alcohol consumption associated with colorectal cancer risk in Quzhou, China: A nested case-control study
    Authors: Lai, S.-M., Zhu, H.-H., Gan, Z.-J., Wang, Z.-C., Liao, X.-F.
    Journal: Preventive Medicine Reports
    Year: 2024

 

  • Antibody responses to an inactivated SARS-CoV-2 vaccine in individuals aged from 50 to 102 years
    Authors: Zhu, H.-H., Sun, G.-Q., Wu, J.-Y., Wang, Z.-C., Liao, X.-F.
    Journal: Frontiers in Immunology
    Year: 2023

Prof Dr. ClausGarbe – Oncology Management and Prevention – Lifetime achievement Award

Prof Dr. ClausGarbe - Oncology Management and Prevention - Lifetime achievement Award

University of Tuebingen - Germany

AUTHOR PROFILE

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Professor Claus Garbe embarked on his academic journey by obtaining his MD from the Free University of Berlin in 1983. Following this, he pursued board certification in Dermatology and Venereology in 1987. His early academic pursuits laid the foundation for his subsequent groundbreaking work in dermatology and oncology.

PROFESSIONAL ENDEAVORS:

In 1990, Professor Garbe achieved his habilitation, akin to a PhD equivalent, with a focus on the biology of melanoma cells. This marked a significant milestone in his academic career, demonstrating his commitment to advancing the understanding of melanoma, a deadly form of skin cancer. In 1995, he transitioned to Eberhard Karls University, Tuebingen, where he assumed the role of University Professor of Dermatology and Head of the Division of Dermatooncology. This move expanded his scope of influence and provided a platform for furthering his research and clinical endeavors.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY MANAGEMENT AND PREVENTION

Professor Garbe's contributions to the field of dermatology and oncology are extensive and profound. His principal research interests encompass the biology and genetics of melanoma and keratinocyte skin cancers, therapeutic trials in skin diseases, epidemiologic studies, and dermato-histopathology. Through his pioneering research, he has elucidated crucial mechanisms underlying skin cancer development and progression, paving the way for innovative therapeutic approaches and preventive strategies.

IMPACT AND INFLUENCE:

Professor Garbe's impact on the field of dermatologic oncology is unparalleled. His leadership roles in numerous multicenter clinical trials since 1989 have facilitated the translation of research findings into clinical practice, ultimately improving patient outcomes. Moreover, his presidency of the European Association of Dermatologic Oncology (EADO) underscores his influence on a global scale, driving collaboration and innovation in the fight against skin cancer.

ACADEMIC CITATIONS:

With over 800 articles and 17 textbooks to his name, Professor Garbe's scholarly output is prolific. His impressive H-index of 116 points reflects the significant impact of his work within the scientific community. His research findings have been cited extensively, highlighting their relevance and contribution to advancing knowledge in dermatology and oncology.

LEGACY AND FUTURE CONTRIBUTIONS:

Professor Garbe's legacy is characterized by his unwavering dedication to advancing the field of dermatologic oncology. His contributions have not only expanded our understanding of skin cancer but have also shaped clinical practice and guidelines. As he continues to spearhead research efforts and mentor the next generation of scientists and clinicians, his legacy is poised to endure, leaving an indelible mark on the field for years to come.

NOTABLE PUBLICATIONS

Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients. 2024 (2)

Sentinel lymph node biopsy for lentigo maligna melanoma under local anaesthesia. 2024 (3)

Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma. 2024 (1)

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. 2023 (6)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. 2023 (2)

Dr. Francesco Raspagliesi – Gynecologic Oncology – Best Researcher Award

Dr. Francesco Raspagliesi - Gynecologic Oncology - Best Researcher Award

Fondazione IRCCS Istituto nazionale Tumori di Milano - Italy  

Author Profile

Scopus

EARLY ACADEMIC PURSUITS

Francesco Raspagliesi began his academic journey with a Degree in Medicine and Surgery from the University of Catania, Italy, which he completed on March 7, 1981. Following this foundational education, he obtained qualifications to practice medicine in 1981 and specialized in Obstetrics and Gynecology from the University of Catania in 1985 and 1988. These early academic pursuits laid the groundwork for his future professional endeavors in the field of gynecologic oncology.

PROFESSIONAL ENDEAVORS

From 1985 to 1992, Raspagliesi served as a Research Fellow at the Fondazione IRCCS Istituto Nazionale Tumori di Milano. He continued his professional growth at the same institution, becoming a Dirigente Medico di 1° Livello from 1992 to 1999 and advancing to Dirigente Medico di 2° Livello Gynecologic Oncology Unit Director from 1999 to 2019. His long-standing association with the Fondazione IRCCS Istituto Nazionale Tumori di Milano demonstrates his commitment and dedication to the field of gynecologic oncology and patient care.

CONTRIBUTIONS AND RESEARCH FOCUS ON GYNECOLOGIC ONCOLOGY

Throughout his career, Raspagliesi has made significant contributions to the field of Obstetrics and Gynecology. His research and clinical work have focused on gynecologic oncology, particularly in the treatment and management of gynecologic cancers. His expertise and leadership as the Gynecologic Oncology Unit Director have contributed to advancements in the diagnosis, treatment, and care of patients with gynecologic cancers.

IMPACT AND INFLUENCE

As a respected figure in the field of gynecologic oncology, Raspagliesi's work has had a profound impact on patient care, research, and education. His leadership roles and contributions to research have helped shape the way gynecologic cancers are treated and managed, influencing clinical practice and improving patient outcomes.

LEGACY AND FUTURE CONTRIBUTIONS

Francesco Raspagliesi's legacy in the field of Obstetrics and Gynecology is characterized by his dedication to patient care, leadership in gynecologic oncology, and contributions to research and education. His continued commitment to advancing the field through research, mentorship, and clinical practice ensures that his influence will be felt by future generations of gynecologic oncologists.

NOTABLE PUBLICATIONS

Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.  2024

Sentinel node mapping in high-intermediate and high-risk endometrial cancer: Analysis of 5-year oncologic outcomes. 2024

Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.  2024

Impact of Cold Ischemia on the Stability of 1H-MRS-Detected Metabolic Profiles of Ovarian Cancer Specimens. 2024

Concurrent Endometrial Cancer in Women with Atypical Endometrial Hyperplasia: What Is the Predictive Value of Patient Characteristics? (2) 2024